Abbott Labs' sales up from successful drug and stent device

New York Abbott Labs rheumatoid arthritis drug Humira (adalimumab) and the stent device Xience pushed the company's sales ahead of its competitors, the drug and device maker announced Wednesday in its fourth-quarter financial report.

Sales of Humira were $1.4 billion for the quarter, while the company sold $410 million worth of stents, more than stent makers Johnson & Johnson and Boston Scientific.Abbott shares increased by $2.33, to $51.53 in afternoon trading Wednesday.